JP2003519481A5 - - Google Patents

Download PDF

Info

Publication number
JP2003519481A5
JP2003519481A5 JP2001551104A JP2001551104A JP2003519481A5 JP 2003519481 A5 JP2003519481 A5 JP 2003519481A5 JP 2001551104 A JP2001551104 A JP 2001551104A JP 2001551104 A JP2001551104 A JP 2001551104A JP 2003519481 A5 JP2003519481 A5 JP 2003519481A5
Authority
JP
Japan
Prior art keywords
polypeptide
ngr
amino acids
seq
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001551104A
Other languages
English (en)
Japanese (ja)
Other versions
JP4763207B2 (ja
JP2003519481A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/001041 external-priority patent/WO2001051520A2/en
Publication of JP2003519481A publication Critical patent/JP2003519481A/ja
Publication of JP2003519481A5 publication Critical patent/JP2003519481A5/ja
Application granted granted Critical
Publication of JP4763207B2 publication Critical patent/JP4763207B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001551104A 2000-01-12 2001-01-12 軸索成長のｎｏｇｏレセプター媒介妨害 Expired - Fee Related JP4763207B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17570700P 2000-01-12 2000-01-12
US60/175,707 2000-01-12
US20736600P 2000-05-26 2000-05-26
US60/207,366 2000-05-26
US23637800P 2000-09-29 2000-09-29
US60/236,378 2000-09-29
PCT/US2001/001041 WO2001051520A2 (en) 2000-01-12 2001-01-12 Nogo receptor-mediated blockade of axonal growth

Publications (3)

Publication Number Publication Date
JP2003519481A JP2003519481A (ja) 2003-06-24
JP2003519481A5 true JP2003519481A5 (https=) 2006-05-11
JP4763207B2 JP4763207B2 (ja) 2011-08-31

Family

ID=27390581

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001551104A Expired - Fee Related JP4763207B2 (ja) 2000-01-12 2001-01-12 軸索成長のｎｏｇｏレセプター媒介妨害

Country Status (27)

Country Link
US (1) US20020012965A1 (https=)
EP (2) EP2163561A1 (https=)
JP (1) JP4763207B2 (https=)
KR (1) KR100828058B1 (https=)
CN (1) CN100354307C (https=)
AT (1) ATE466882T1 (https=)
AU (1) AU784349C (https=)
BG (1) BG106907A (https=)
BR (1) BR0107613A (https=)
CA (1) CA2397199C (https=)
CZ (1) CZ20022438A3 (https=)
DE (1) DE60142023D1 (https=)
EA (1) EA008480B1 (https=)
EE (1) EE200200386A (https=)
ES (1) ES2341842T3 (https=)
GE (1) GEP20063830B (https=)
HK (1) HK1051543A1 (https=)
HU (1) HUP0203863A3 (https=)
IL (2) IL150566A0 (https=)
IS (1) IS6455A (https=)
MX (1) MXPA02006885A (https=)
NO (1) NO20023387L (https=)
NZ (2) NZ520065A (https=)
PL (1) PL356887A1 (https=)
SK (1) SK9992002A3 (https=)
WO (1) WO2001051520A2 (https=)
YU (1) YU53502A (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066041A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
US7723488B2 (en) 1998-03-27 2010-05-25 Genentech, Inc. Monoclonal antibodies to secreted and transmembrane polypeptides
US7371836B2 (en) 1998-03-27 2008-05-13 Genentech, Inc. PRO526 nucleic acids
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
IL150566A0 (en) * 2000-01-12 2003-02-12 Univ Yale Nucleic acids and polypeptides and nogo-receptor proteins
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
NZ525422A (en) 2000-10-06 2006-09-29 Biogen Idec Inc Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons
GB0101313D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
GB0101312D0 (en) 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
JP2005507246A (ja) * 2001-08-27 2005-03-17 ノバルティス アクチエンゲゼルシャフト Ｎｏｇｏレセプターホモログおよびそれらの使用
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
FR2841261B1 (fr) * 2002-06-25 2004-08-27 Univ Pasteur Compositions et methodes pour detecter les pathologies affectant la transmission neuromusculaire
EP1534736B1 (en) * 2002-08-10 2010-06-02 Yale University Nogo receptor antagonists
PT1534736E (pt) 2002-08-10 2010-09-07 Univ Yale Antagonistas do receptor nogo
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
CN1745094A (zh) * 2002-12-06 2006-03-08 新加坡综合医院有限公司 肽,其抗体,以及它们在中枢神经系统损伤的治疗中的用途
US7842666B2 (en) * 2002-12-20 2010-11-30 Research Foundation Of City University Of New York Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
US7541335B2 (en) 2003-04-04 2009-06-02 University Of Rochester Nogo-receptors and methods of use
EP1615654A2 (en) * 2003-04-16 2006-01-18 Yale University Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
AU2004247018A1 (en) * 2003-05-15 2004-12-23 Bayhill Therapeutics, Inc. Novel immunomodulating peptide
EP3514238B1 (en) * 2003-05-16 2021-05-05 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
WO2005059515A2 (en) * 2003-12-16 2005-06-30 Children's Medical Center Corporation Method for treating neurological disorders
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
WO2006047049A2 (en) * 2004-10-01 2006-05-04 Yale University Nogo-a polypeptide fragments, variant nogo receptor-1 polypeptides, and uses thereof
US20090137484A1 (en) * 2004-12-01 2009-05-28 National University Of Singapore Neuronal Network-Interacting Peptide
US7893032B2 (en) 2005-07-07 2011-02-22 Yale University NgR variants and compositions thereof for suppressing axonal growth inhibition
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
CA2913655A1 (en) 2006-01-27 2007-08-09 Biogen Ma Inc. Nogo receptor antagonists
JP2009538282A (ja) * 2006-05-15 2009-11-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 乏突起膠細胞の生存を促進させるためのＮｏｇｏ受容体−１（ＮｇＲ１）アンタゴニストの使用
JP2009544703A (ja) 2006-07-24 2009-12-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法
MX2009005361A (es) 2006-11-21 2009-06-05 Abbott Lab Anticuerpos monoclonales neutralizantes contra el receptor de nogo-66 (ngr) y usos de los mismos.
EP2276500A4 (en) 2008-03-13 2015-03-04 Univ Yale REACTIVATION OF AXON GROWTH AND AXON RECOVERY IN CHRONIC REVERSE MARKET INJURIES
CL2009001155A1 (es) * 2008-05-13 2010-06-04 Genentech Inc Anticuerpo anti-pirb/lilrb aislado; polinucleotido que lo codifica; vector; celula huesped; metodo de obtencion; composicion farmaceutica que lo comprende; kit; y su uso para tratar enfermedades neurodegenerativas.
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
CN104470541A (zh) 2012-05-14 2015-03-25 比奥根艾迪克Ma公司 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
CN104935294B (zh) * 2014-03-20 2018-07-20 晶宏半导体股份有限公司 振荡器
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
CN105061560B (zh) * 2015-07-17 2018-10-09 暨南大学 一种Nogo-A受体结合肽及其衍生物与应用
CN113527462B (zh) * 2020-04-22 2023-05-23 北京大学 一种具有镇痛作用的小分子肽及其特异性抗体

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4839288A (en) 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US5466585A (en) 1986-04-15 1995-11-14 Ciba-Geigy Corporation Interferon-induced human protein in pure form, monoclonal antibodies thereto, and test kits containing these antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
CA1315719C (en) 1988-02-05 1993-04-06 Arthur Bank Retroviral packaging cell lines and processes of using same
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
CA1341050C (en) 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
DE68923362T2 (de) 1988-11-04 1996-03-28 Zuerich Erziehungsdirektion Wachstumsregelfaktoren für neuriten.
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5723719A (en) 1991-08-08 1998-03-03 Health Research Inc. Transgenic mouse as model for diseases involving dopaminergic dysfunction
DE4126968A1 (de) 1991-08-14 1993-02-18 Detlev Prof Dr Med Ganten Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist
ATE273386T1 (de) 1991-09-20 2004-08-15 Hutchinson Fred Cancer Res Menschliches cyclin e
EP0620849B1 (en) 1992-01-07 2003-06-25 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
US5733720A (en) 1992-06-18 1998-03-31 Washington University Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor
US5602307A (en) 1992-08-12 1997-02-11 Baylor College Of Medicine Non-human animal having predefined allele of a cellular adhesion gene
US5731490A (en) 1992-09-29 1998-03-24 The Ontario Cancer Institute Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)
WO1994017831A1 (en) 1993-02-11 1994-08-18 Erziehungsdirektion Of The Canton Zurich A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
DK75393D0 (da) 1993-06-24 1993-06-24 Symbicom Ab Production of protein
ATE424927T1 (de) 1993-10-28 2009-03-15 Houston Advanced Res Ct Mikrofabriziertes poröses durchflussgerät zur diskreten bestimmung von bindungsreaktionen
MX198456B (es) 1994-03-09 2000-09-05 Abbott Lab Animales trangenicos que producen oligosacaridos y glucoconjugados.
FR2718329B1 (fr) 1994-03-21 2002-09-20 Rhone Poulenc Rorer Sa Lapin transgénique sensibilisé aux dyslipoprotéinémies.
US5908969A (en) 1994-05-13 1999-06-01 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same
WO2000073452A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5728915A (en) 1995-05-08 1998-03-17 Children's Hospital, Inc. Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US5961976A (en) 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
US5858708A (en) 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
WO2000053756A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999066041A1 (en) * 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
WO2000070050A1 (en) * 1999-05-14 2000-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2311640A1 (en) * 1997-12-03 1999-06-10 Genentech, Inc. Polypeptides and nucleic acids encoding the same
JP3868740B2 (ja) * 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド 新規なポリペプチド及びそれをコードする核酸
AU762055B2 (en) * 1998-03-10 2003-06-19 Genentech Inc. Novel polypeptides and nucleic acids encoding the same
AU3134799A (en) 1998-04-16 1999-11-08 Peter Erich Braun Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
CA2324297A1 (en) * 1998-04-23 1999-10-28 Genentech, Inc. Sh2 domain-containing peptides
CA2326001A1 (en) * 1998-04-24 1999-11-04 Genentech, Inc. Fizz proteins
AU761340B2 (en) * 1998-06-02 2003-06-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CZ304224B6 (cs) * 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
KR100529270B1 (ko) * 1998-12-01 2005-11-21 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
JP3993746B2 (ja) * 1998-12-22 2007-10-17 ジェネンテック・インコーポレーテッド 腫瘍性細胞成長阻害のための組成物及び方法
CA2362427A1 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2383592A1 (en) * 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
WO2001009162A2 (en) * 1999-07-30 2001-02-08 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
IL150566A0 (en) * 2000-01-12 2003-02-12 Univ Yale Nucleic acids and polypeptides and nogo-receptor proteins

Similar Documents

Publication Publication Date Title
JP2003519481A5 (https=)
JP2005508165A5 (https=)
JP5738294B2 (ja) 抗ｖｅｇｆモノクローナル抗体およびその抗体を含む薬学的組成物
Honda et al. The coxsackievirus-adenovirus receptor protein as a cell adhesion molecule in the developing mouse brain
EP1181318B1 (en) Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
JP4938957B2 (ja) Ｃｄ３０またはｃｄ３０ｌのアンタゴニストを使用する自己免疫および慢性炎症性状態の処置法
KR102040235B1 (ko) RGMa 결합 단백질 및 그 사용
KR20190127703A (ko) 수의학적 용도를 위한 항-il31 항체
JP2011527572A5 (https=)
JP7742433B2 (ja) 末梢神経障害又は末梢神経障害若しくはアストロサイト障害が認められる疾患に伴う疼痛の予防又は治療方法
JP2004507559A5 (https=)
KR20180134876A (ko) 인간화 항 clever-1 항체 및 이의 용도
Cao et al. Integrin β1 is involved in the signaling of glial cell line‐derived neurotrophic factor
UA76396C2 (en) Monoclonal antibody, which is able to be bound with receptor ifn -, block the biological activity of ifn- and ifn- and create higher antiviral titer against fn-, than against ifn- (variants), pharmaceutical composition for modulation or blocking biological activity of ifn-, hybridoma expressing denoted antibody (variants), and set for carrying out elisa-analysis of ifnab-bpi and/or ifnab-bpi
US20250134959A1 (en) Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders
King et al. Immunohistochemical expression of the α5 integrin subunit in the normal adult rat central nervous system
JP2003510078A5 (https=)
Nakao et al. Distribution of OL-protocadherin in axon fibers in the developing chick nervous system
JP2004515215A5 (https=)
CN103638521A (zh) 神经延长促进剂及延长抑制剂
EP4118116A1 (en) Musk agonist antibody
EP3116526B1 (en) Pharmaceutical compositions comprising april for use the treatment of multiple sclerosis, autoimmune encephalitis, neuromyelitis optica, alzheimer disease or parkinson disease
RU2822199C2 (ru) Способ предупреждения или лечения периферической нейропатии или боли, сопровождающей заболевание, при котором выявлена периферическая нейропатия или нарушение астроцитов
CN113614112A (zh) MuSK抑制
TW202523690A (zh) 由脊髓或腦之障礙引起之疾病所伴隨之伴隨症狀之預防或治療劑